

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

--39³. (New) The recombinant virus of claim 38² which comprises at least three foreign nucleic acids, each inserted within a non-essential region of the viral genome.

--40⁴. (New) The recombinant virus of claim 38² which comprises four foreign nucleic acids, each inserted within a non-essential region of the viral genome.

--41⁵. (New) The recombinant virus of claim 37¹, wherein the virus is raccoonpox virus, a swinepox virus, or a feline herpesvirus.

--42⁶. (New) The recombinant virus of claim 37¹ comprising more than one foreign nucleic acid, wherein each foreign nucleic acids is inserted into the same nonessential region.

--43. (New) The recombinant virus of claim 37¹ comprising more than one foreign nucleic acid wherein all such foreing nucleic acids are not inserted into the same nonessential region.

--44⁸. (New) The recombinant virus of claim 37¹ further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen.

--45⁹. (New) The recombinant virus of claim 44⁸, wherein the pathogen is a feline pathogen, a rabies virus, Chlamydia, Taxoplasmosis gondii, Dirofilaria immitis, a flea, or a bacterial pathogen.

--46¹⁰. (New) The recombinant virus of claim 45⁹, wherein the feline pathogen is feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), feline infectious peritonitis virus (FIP), feline panleukopenia virus, feline calicivirus, feline reovirus type 3, feline

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

rotavirus, feline coronavirus, feline syncytial virus, feline sarcoma virus, feline herpesvirus, feline Borna disease virus, or a feline parasite.

--47. ¹¹ (New) The recombinant virus of claim ³⁷, wherein at least one foreign nucleic acid comprises a promoter for expressing the foreign nucleic acid.

~~B / each~~
--48. ¹² (New) The recombinant virus of claim ³⁷, wherein the expression of at least one foreign nucleic acids is under the control of a promoter ~~endogenous~~ ^{endogenous} to the virus.

--49. ¹³ (New) The recombinant virus of claim ³⁷ further comprising a foreign nucleic acid encoding a detectable marker.

--50. ¹⁴ (New) The recombinant virus of claim ⁴⁹, wherein the detectable marker is E.coli beta galactosidase.

--51. ¹⁵ (New) The recombinant virus of claim ⁴⁶, wherein the immunogen from a feline pathogen is FIV gag protease, a FIV envelope protein, a FeLV gag protease, or a FeLV envelope protein.

--52. ¹⁶ (New) The recombinant virus of claim ³⁷, wherein the virus is a feline herpesvirus and the a nonessential region is the glycoprotein G gene of feline herpes virus.

Sub D2 ¹⁷
--53. (New) The recombinant feline herpesvirus of claim ⁴⁸ ¹² designated S-FHV-031 (ATCC Accession No. VR-2604).

--54. ¹⁸ (New) The recombinant virus of claim ³⁷, wherein the virus is swinepox virus and the nonessential region is the larger Hind III to Bgl II subfragment of the Hind III M fragment of swinepox virus.

a

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

--55.¹⁹ (New) The recombinant feline swinepox of claim 50¹⁴
designated S-SPV-246 (ATCC Accession No. VR-2603).

Sub D3
--56.²⁰ (New) The recombinant virus of any of claim 37¹, wherein
the portion of the CD28, CD80, or CD86 protein is the
soluble portion of the protein.

cont
--57.²¹ (New) The recombinant virus of claim 37¹, where the
foreign nucleic acid encodes the feline CTLA-4 protein.

--58.²² (New) A vaccine which comprising an effective immunizing
amount of the recombinant virus of claim 37¹ and a
suitable carrier.

Sub D4
--59.²³ (New) The vaccine of claim 58, wherein the effective
immunizing amount of the recombinant virus is an amount
between about 1×10^5 pfu/ml and about 1×10^6 cfu/ml.

--60.²⁴ (New) The vaccine of claims 58 which further comprises
an admixture with the recombinant virus an effective
immunizing amount of a second immunogen.

--61.²⁵ (New) A method for enhancing an immune response in a
feline which comprises administering to the feline an
effective immunizing amount of the recombinant virus of
claim 37¹.

Sub D5
--62.²⁶ (New) A method for immunizing a feline which comprising
administering to the feline an effective immunizing
amount of the recombinant virus of claim 37¹.

--63.²⁷ (New) A method for suppressing an immune response in a
feline which comprises administering to the feline any
effective suppressing amount of the recombinant virus of
claim 56.²⁰

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

cont.

--64. ²⁸ (New) The method of claim ⁶¹, wherein the administering comprises intravenous, subcutaneous, intramuscular, transmuscular, topical, oral, or intraperitoneal administration.

--65. ²⁹ (New) The method of claim ⁶³, wherein the feline is the recipient of a transplanted organ or tissue or is suffering from an immune response.

--66. (New) A method for suppressing an immune response in a feline which comprises administering to the feline an antisense nucleic acid capable of hybridizing to and inhibiting translation of: (a) a feline CD28 mRNA transcript, (b) a feline CD80 transcript, or (c) a feline CD86 mRNA transcript the antisense nucleic acid being present in an amount effective to inhibit translation and thus suppress the immune response in the feline.

--67. ³⁰ (New) A method for reducing or abrogating a tumor in a feline which comprises administering to the tumor in the feline a recombinant virus of claim ²⁷, wherein the nucleic acid encodes a feline CD80 protein, a feline CD86 protein or a combination thereof in an amount effective reduce or abrogate the tumor.

--68. ³¹ (New) The method of claim ⁶⁷, wherein the recombinant virus further comprises, and is capable of expressing, a feline tumor associated antigen and the administration is effected systemically.

--69. ³² (New) The recombinant virus of claim ²⁷, further comprising a nucleic acid encoding feline immunodeficiency virus genome or a portion thereof.

--70. ³³ (New) The recombinant virus of claim ²⁷, further

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

comprising a nucleic acid encoding feline leukemia virus genome or a portion thereof.

1 claim 36-39

Sub C 3

--71. (New) The recombinant virus of claim 69, further comprising a nucleic acid encoding feline IL12, p35 or p40.

--72. (New) The recombinant virus of claim 70, further comprising a nucleic acid encoding feline IL12, p35 or p40.

36-39

--73. (New) A vaccine which comprises an effective immunizing amount of the recombinant virus of claim ~~69~~²⁵³² and a suitable carrier.

37-50

--74. (New) A vaccine which comprises an effective immunizing amount of the recombinant virus of claim ~~70~~²⁶³³ and a suitable carrier.

REMARKS

Claims 1-36 were pending in the subject application. By this amendment applicants have canceled claims 1-36 without prejudice or disclaimer, and added new claims 37-74. Accordingly, upon entry of this Amendment, claims 37-74, will be pending and under examination.

Applicants maintain that new claims 37-74 raise no issue of new matter. According, the entry of this Preliminary Amendment and the allowance of the claims now pending in this application are respectfully requested.

a